Recursion Pharmaceuticals raised $50 million from Nvidia via a PIPE that placed the AI biotech squarely into the investor fervor surrounding the tech company.
Recursion said Wednesday morning it now plans to work with Nvidia on the software company’s cloud service that uses generative AI for drug discovery. Recursion brings a massive biochemical dataset through which Nvidia’s drug discovery foundation models can be trained.
On the flip side, Recursion will also get Nvidia’s help with its foundation models, and will use its cloud service internally as well as with its “current and future partners.”
Biotechs and tech companies have flaunted AI as a solution for one of biotech’s many bottlenecks: drug discovery. Investors have greeted AI (and Nvidia, in particular) with a frenzy, and Wednesday’s announcement followed suit.
Recursion — which has seen its share price fall by nearly one-third over the past month — saw its stock Click here to view original post
